¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"localization related epilepsy"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • nocturnal epilepsy
    ¾ß°£°£Áú
  • organic epilepsy
    ±âÁú¼º°£Áú
  • photic epilepsy
    ºûÀ¯¹ß°£Áú, ±¤À¯¹ß°£Áú
  • photogenic epilepsy
    ºûÀ¯¹ß°£Áú, ±¤À¯¹ß°£Áú
  • photosensitive epilepsy
    ºû¹Î°¨°£Áú, ±¤¹Î°¨°£Áú
  • post-apoplectic epilepsy
    ³úÁ¹ÁßÈİ£Áú
  • post-stroke epilepsy
    ³úÁ¹ÁßÈİ£Áú
  • post-traumatic epilepsy
    ¿Ü»óÈİ£Áú
  • psychomotor epilepsy
    Á¤½Å¿îµ¿°£Áú
  • petit mal epilepsy
    ¼Ò¹ßÀÛ°£Áú
  • running epilepsy
    ÁúÁÖ°£Áú
  • reflex epilepsy
    ¹Ý»ç°£Áú
  • sensory epilepsy
    °¨°¢°£Áú
  • temporal lobe epilepsy
    °üÀÚ¿±°£Áú, ÃøµÎ¿±°£Áú
  • tardy epilepsy
    ¸¸±â°£Áú
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • morpheic epilepsy
    ¼ö¸éÇü°£Áú
  • myoclonic epilepsy
    °£´ë¼º±Ù°æ·Ã°£Áú
  • neonatal epilepsy
    ½Å»ý¾Æ°£Áú
  • nocturnal epilepsy
    ¾ß°£°£Áú
  • organic epilepsy
    ±âÁú¼º°£Áú
  • petit mal epilepsy
    ¼Ò¹ßÀÛ°£Áú
  • photic epilepsy
    ±¤¼±°£Áú, ºûÀ¯¹ß°£Áú
  • photogenic epilepsy
    ±¤¼±°£Áú, ºûÀ¯¹ß°£Áú
  • photosensitive epilepsy
    ±¤¼±¹Î°¨°£Áú, ºû¹Î°¨°£Áú
  • post-apoplectic epilepsy
    ³úÁßdzÈİ£Áú
  • post-stroke epilepsy
    ³úÁßdzÈİ£Áú
  • post-traumatic epilepsy
    ¿Ü»óÈİ£Áú
  • primary epilepsy
    ¿ø¹ß°£Áú, ÀÏÂ÷°£Áú
  • psychomotor epilepsy
    Á¤½Å¿îµ¿°£Áú
  • reflex epilepsy
    ¹Ý»ç°£Áú
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • posttraumatic epilepsy
    ¿Ü»óÈİ£Áú.
  • premenstrual epilepsy
    ¿ù°æÀü°£Áú (¡­ÊÖòð).
  • premenstrual epilepsy
    ¿ù°æÀü°£Áú(êÅÌèîñÊÖòð)
  • primary epilepsy
    ÀÏÂ÷¼º¡¡°£Áú
  • primary epilepsy
    ¿ø¹ß(¼º) °£Áú(ê«Û¡(àõ) ÊÖòð)
  • primary epilepsy
    ¿ø¹ß(¼º) °£Áú(ê«Û¡àõ ÊÖòð).
  • procursive epilepsy
    ÁúÁÖ¼º °£Áú(òðñËàõ ÊÖòð).
  • reactive epilepsy
    ¹ÝÀÀ¼º °£Áú(¡­ÊÖòð).
  • reactive epilepsy
    ¹ÝÀÀ¼º °£Áú(ÚãëëàõÊÖòð)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • opioid-related disorder
    ¾ÆÆí¾çÁ¦Á¦ °ü·ÃÀå¾Ö(μ֤î¡äô)(º´)
  • parathyroid hormone-related peptide
    ºÎ°©»ó¼±(ÜùË£ßÒàÍ)È£¸£¸ó¿¬°ü(¡­æáμ)ÆéŸÀ̵å
  • polysubstance-related disorder
    º¹ÇÕ¹°Áú°ü·ÃÀå¾Ö(º´)
  • related
    ±ÙÄ£(ÐÎöÑ)ÀÇ.
  • sleep-related disorders
    ¼ö¸é°ü·ÃÀå¾Ö(º´)
  • steroid-related disorders
    ½ºÅ×·ÎÀÌµå °ü·ÃÀå¾Ö(º´).
  • stress-related disorders
    ½ºÆ®·¹½º °ü·ÃÀå¾Ö(º´).
  • tobacco-related disorders
    Åä¹ÙÄÚ(´ã¹è)°ü·ÃÀå¾Ö(~º´).
  • transfusion-related
    ¼öÇ÷-¿¬°üÀÇ
  • abdominal epilepsy
  • abortive epilepsy
    ºÎÀü°£Áú.
  • affect epilepsy
    Á¤µ¿¼º °£Áú(ï×ÔÑàõÊÖòð).
  • akinetic epilepsy
    ¹«µ¿¼º °£Áú(¡­ÊÖòð).
  • alcoholic epilepsy
    ¾ËÄڿüº °£Áú(¡­ÊÖòð).
  • arithmetical epilepsy
    »ê¼ú¼º °£Áú
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
BOE benign occipital epilepsy
BPEC benign partial epilepsy of childhood; bipolar electrocardiogram
CE California encephalitis; cardiac enlargement; cardioesophageal; carotid endarterectomy; catamenial e...
DME degenerative myoclonus epilepsy; dimethyl diester; dimethyl ether; diphasic meningoencephalitis; dir...
EAA electroacupuncture analgesia; Epilepsy Association of America; essential amino acid; excitatory amin...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
IGE Idiopathic Generalized Epilepsy
ILAE International League Against Epilepsy
JME Juvenile Myoclonic Epilepsy
JAE Juvenile absence epilepsy
MTLE Medial temporal lobe epilepsy
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
prosthesis-related infections Infections resulting from the implantation of prosthetic devices. The infections may be acquired from intraoperative contamination (early) or haematogenously acquired from other sites (late).
(12 Dec 1998)
src-related intestinal kinase <enzyme> An intracellular epithelial cell tyrosine kinase; shares 80% homology with human tyrosine kinase brk; has 451 amino acid residues; amino acid sequence given in first source
Registry number: EC 2.7.1.-
Synonym: sik protein, sik gene product
(26 Jun 1999)
substance-related disorders These non-psychotic disorders include those related to the taking of a drug of abuse (including alcohol), to the side effects of a medication, and to toxin exposure.
(12 Dec 1998)
diabetes related peptide <hormone, protein> Peptide of 37 amino acids that selectively inhibits insulin stimulated glucose uptake in muscle. Structurally related to calcitonin gene-related peptide.
(15 Oct 1997)
diagnosis-related group A classification of patients by diagnosis or surgical procedure (sometimes including age) into major diagnostic categories (each containing specific diseases, disorders, or procedures) for the purpose of determining payment of hospitalization charges, based on the premise that treatment of similar medical diagnoses generate similar costs.
A scheme for billing for medical and especially hospital services by combining diseases into groups according to the resources needed for care, arranged by diagnostic category. A dollar value is assigned to each group as the basis of payment for all cases in that group, without regard to the actual cost of care or duration of hospitalization of any individual case, as a mechanism to motivate health-care providers to economise.
(05 Mar 2000)
diagnosis-related groups A system for classifying patient care by relating common characteristics such as diagnosis, treatment, and age to an expected consumption of hospital resources and length of stay. Its purpose is to provide a framework for specifying case mix and to reduce hospital costs and reimbursements and it forms the cornerstone of the prospective payment system.
(12 Dec 1998)
diseases, obesity-related Obesity increases the risk of developing a number of diseases including: Type 2 (adult-onset) diabetes High blood pressure (hypertension) Stroke (cerebrovascular accident or CVA) Heart attack (myocardial infarction or MI) Heart failure (congestive heart failure) Cancer (only certain forms such as prostate and colon cancer) Gallstones and gall bladder disease (cholecystitis) Gout and gouty arthritis Osteoarthritis (degenerative arthritis) of the knees, hips, and the lower back Sleep apnea (failure to breath normally during sleep, lowering blood oxygen) Pickwickian syndrome (obesity, red face, underventilation, and drowsiness).
(12 Dec 1998)
islet cell antigen-related protein-tyrosine phosphatase <enzyme> Receptor-like autoantigen found in insulin-dependent diabetes; genbank l76258
Registry number: EC 3.1.3.-
Synonym: iar ptp
(26 Jun 1999)
obesity-related diseases Obesity increases the risk of developing a number of diseases including: type 2 (adult-onset) diabetes high blood pressure (hypertension) stroke (cerebrovascular accident or cva) heart attack (myocardial infarction or mi) heart failure (congestive heart failure) cancer (only certain forms such as prostate and colon cancer) gallstones and gall bladder disease (cholecystitis) gout and gouty arthritis osteoarthritis (degenerative arthritis) of the knees, hips, and the lower back sleep apnea (failure to breath normally during sleep, lowering blood oxygen) pickwickian syndrome (obesity, red face, underventilation, and drowsiness).
(12 Dec 1998)
opioid-related disorders Disorders related or resulting from abuse or mis-use of opioids.
(12 Dec 1998)
event-related potentials, p300 A late-appearing component of the event-related potential. P stands for positive voltage potential and 300 represents 300 millisecond poststimulus. Its amplitude increases with unpredictable, unlikely, or highly significant stimuli and thereby constitutes an index of mental activity.
(12 Dec 1998)
fos-related antigen <molecular biology> A group of phosphoproteins found in the cell nucleus which are structurally similar to the fos oncogene's gene product.
(06 Mar 1998)
FYN-related kinase <enzyme> 49% identical to human fyn and 47% to human src; genbank u00803
Registry number: EC 2.7.1.-
Synonym: frk protein, frk gene product
(26 Jun 1999)
light chain-related amyloidosis A form of primary amyloidosis in which the fibrillar amyloid deposits are derived from the amino terminal variable region of the light chains of immunoglobulin; seen in B-lymphocyte and plasma-cells dyscrasias.
(05 Mar 2000)
lymphoma, aids-related B-cell lymphoid tumours that occur in association with aids. Patients often present with an advanced stage of disease and highly malignant subtypes including burkitt lymphoma, immunoblastic large-cell lymphoma, small non-cleaved-cell lymphoma and diffuse large-cell lymphoma. The tumours are often disseminated in unusual extranodal sites and chromosomal abnormalities are frequently present. It is likely that polyclonal B-cell lymphoproliferation in aids is a complex result of ebv infection, HIV antigenic stimulation, and T-cell-dependent HIV activation.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á